2seventy bio Inc. stock TSVT rose 2.7% in premarket trading on Tuesday after the T-cell drug company for cancer treatment said it’s cutting 176 jobs or 40% of its work force and launching a search for a new chief executive. Current chief executive Nick Leschly will become chairman of the company’s board. The company said the job cuts will generate more than $130 million in cost savings. It’ll advance fewer drug pipeline programs while building up its collaboration with JW Therapeutics HK:2126 to include new solid tumor and autoimmune programs. 2seventy bio said it no longer expects to generate $470 million to $570 million in 2023 revenue, as sales of its Abecma gene therapy medicine to treat multiple myeloma have declined. 2seventy said it will take a one-time restructuring charge of $9 million for the job cuts.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.